1. von Herbay A, Illes A, Waldherr R, et al. Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer, 1990, 66(3): 587-592.
[2]
2. Uruga H, Fujii T, Kurosaki A. Pulmonary tumor thrombotic microangiopathy: a clinical analysis of 30 autopsy cases. Intern Med, 2013, 52(12): 1317-1323.
[3]
3. Chinen K, Tokuda Y, Fujiwara M. Pulmonary tumor thrombotic microangiopathy in patients with gastric carcinoma: an analysis of 6 autopsy cases and review of the literature. Pathol Res Pract, 2010, 206(10): 682-689.
[4]
4. Higo K, Kubota K, Takeda A. Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med, 2014, 53(22): 2595-2599.
6. Higashi A, Dohi Y, Uraoka N. The potential role of inflammation associated with interaction between osteopontin and CD44 in a case of pulmonary tumor thrombotic microangiopathy caused by breast cancer. Intern Med, 2015, 54(22): 2877-2880.
[7]
7. Takahashi F, Kumasaka T, Nagaoka T. Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol Int, 2009, 59(10): 752-756.
10. Fukada I, Araki K, Kobayashi K, et al. Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer. Springerplus, 2016, 5(1): 1582.